ArticleNeurogastroenterology and motility2026
Tardive Dyskinesia in Patients Receiving Continuous Versus Intermittent Oral Metoclopramide: A Retrospective Real World Study.
Article in Neurogastroenterology and motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTardive dyskinesia (TD) is an often irreversible movement disorder associated with prolonged exposure to dopamine receptor antagonists such as metoclopramide (MCP). This study evaluates the prevalence and timing of TD in patients receiving continuous versus intermittent MCP.
methodsA retrospective analysis was conducted using Symphony Health Solutions data from July 2018 to June 2024, covering over 307 million U.S. PATIENTS: Two cohorts were analyzed: (1) all patients with ≥ 2 MCP prescriptions (Cohort A), and (2) patients with a gastroparesis diagnosis (ICD10 K31.84) prior to ≥ 2 MCP prescriptions (Cohort B). TD prevalence was evaluated based on ≥ 1 or ≥ 2 ICD-10 G24.01 claims within 12 months after initial MCP prescription. MCP exposure was classified as continuous (Proportion of days covered (PDC) > = 1) or intermittent (PDC < 1).
resultsTD prevalence was higher in patients receiving continuous MCP across both cohorts. In Cohort A (N = 1,360,196), TD prevalence was 0.25% (continuous) vs. 0.18% (intermittent) for ≥ 1 claim, and 0.13% vs. 0.09% for ≥ 2 claims. In the cohort with gastroparesis (N = 125,279), TD prevalence was 0.77% (continuous) vs. 0.55% (intermittent) for ≥ 1 claim, and 0.43% vs. 0.25% for ≥ 2 claims. Median time to TD diagnosis was shorter for continuous users: 567 vs. 758 days in Cohort A and 490 vs. 573 days in Cohort B. All group differences were statistically significant (p < 0.005).
conclusionsContinuous MCP dosing was associated with higher TD prevalence and earlier onset. Intermittent dosing, despite longer cumulative exposure, was associated with lower TD risk. These findings suggest that intermittent regimens may offer a safer MCP therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.